Vertex Pharmaceuticals said Thursday that it would shelve an experimental protein “corrector” drug — the highest-priority medicine in the biotech’s pipeline — after it failed to achieve the goals of a small clinical trial involving patients with an inherited disorder that causes serious damage to the liver and lungs.
The failure of the oral drug, called VX-864, is the second setback for Vertex and its effort to develop a treatment for patients with a genetic disease called alpha-1 antitrypsin deficiency, or AATD. The company’s first attempt, with a different drug, was shelved due to liver toxicity last year.
Create a display name to comment
This name will appear with your comment